Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance

[1]  Christopher T. Johnson,et al.  Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites , 2017, Science Advances.

[2]  C. Ricordi,et al.  Bioengineering of an Intraabdominal Endocrine Pancreas. , 2017, The New England journal of medicine.

[3]  C. Ricordi,et al.  Bioengineering the Endocrine Pancreas: Intraomental Islet Transplantation Within a Biologic Resorbable Scaffold , 2016, Diabetes.

[4]  T. Curiel,et al.  Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice , 2015, Aging cell.

[5]  Andrés J. García,et al.  Microfluidic‐Based Generation of Size‐Controlled, Biofunctionalized Synthetic Polymer Microgels for Cell Encapsulation , 2014, Advanced materials.

[6]  W. R. Taylor,et al.  Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes. , 2013, Biomaterials.

[7]  U. Boggi,et al.  Long-Term (5 Years) Efficacy and Safety of Pancreas Transplantation Alone in Type 1 Diabetic Patients , 2012, Transplantation.

[8]  Jay C. Sy,et al.  Maleimide Cross‐Linked Bioactive PEG Hydrogel Exhibits Improved Reaction Kinetics and Cross‐Linking for Cell Encapsulation and In Situ Delivery , 2012, Advanced materials.

[9]  C. Lacelle,et al.  Pancreatic Islets Engineered with SA-FasL Protein Establish Robust Localized Tolerance by Inducing Regulatory T Cells in Mice , 2011, The Journal of Immunology.

[10]  V. Rodrik-Outmezguine,et al.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1 , 2011, Cell cycle.

[11]  Qingsheng Li,et al.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. , 2010, Immunity.

[12]  Elizabeth A. Kruse,et al.  Membrane-bound but not Secreted Fas Ligand Is Essential for Fas-Induced Apoptosis and Prevention of Autoimmunity and Cancer , 2009, Nature.

[13]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[14]  I. T. Ten Berge,et al.  Intragraft FOXP3 Protein or mRNA During Acute Renal Allograft Rejection Correlates With Inflammation, Fibrosis, and Poor Renal Outcome , 2009, Transplantation.

[15]  Y. Sagiv,et al.  Apoptosis as a mechanism of T‐regulatory cell homeostasis and suppression , 2008, Immunology and cell biology.

[16]  G. Jhangri,et al.  FOXP3 Expression in Human Kidney Transplant Biopsies Is Associated with Rejection and Time Post Transplant but Not with Favorable Outcomes , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  C. June,et al.  Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1 , 2008, The Journal of Immunology.

[18]  M. Márques,et al.  Tacrolimus‐Induced Diabetes in Rats Courses with Suppressed Insulin Gene Expression in Pancreatic Islets , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  G. Eisenbarth,et al.  Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. , 2007, The Journal of clinical investigation.

[20]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[21]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.

[22]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[23]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[24]  Yuichiro Yamada,et al.  Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. , 2005, American journal of physiology. Endocrinology and metabolism.

[25]  Narendra P. Singh,et al.  Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. , 2002, Immunity.

[26]  B. Malassagne,et al.  Transgenic Expression of CD95 Ligand on Thyroid Follicular Cells Confers Immune Privilege upon Thyroid Allografts , 2001, The Journal of Immunology.

[27]  R. Gorczynski,et al.  Dendritic Cells Genetically Engineered to Express Fas Ligand Induce Donor-Specific Hyporesponsiveness and Prolong Allograft Survival1 , 2000, The Journal of Immunology.

[28]  K. Okumura,et al.  Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells , 1999, Nature Medicine.

[29]  R. Sherwin,et al.  Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in β Cells , 1999 .

[30]  F. Dallegri,et al.  Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.

[31]  Å. Lernmark,et al.  Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. , 1999, Diabetes.

[32]  M. Monden,et al.  Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts , 1998, Diabetologia.

[33]  C. Ricordi,et al.  Long-Term Function (6 Years) of Islet Allografts in Type 1 Diabetes , 1997, Diabetes.

[34]  G. Nabel,et al.  Inhibition of the alloantibody response by CD95 ligand , 1997, Nature Medicine.

[35]  D. Hanahan,et al.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction , 1997, Nature Medicine.

[36]  J. Pepose,et al.  CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. , 1997, The Journal of clinical investigation.

[37]  C. Stoeckert,et al.  Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice , 1996, Science.

[38]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[39]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[40]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[41]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[42]  K. Haskins,et al.  Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. , 1990, Science.

[43]  Bart O. Roep,et al.  T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins , 1990, Nature.

[44]  R. Negrin,et al.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. , 2008, Blood.